Reference number : GC-2017-Q3-00456, amendment number : , agreement type : G, recipient legal name : Keshavarz Motamed, Zahra (McMaster University), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : COMPANY BACKGROUND: ViVitro Labs Inc. is a Canadian-based company that has provided_x000D_
cardiovascular and endovascular device test equipment and laboratory testing to a global market. It is the only_x000D_
Canadian company making cardiovascular and endovascular device test simulators. The ViVitro Pulse_x000D_
Duplicator system is the world's most cited and used in vitro hemodynamic testing system for commercial heart_x000D_
and valve devices. THE NEED: Although the ViVitro simulators have the capability of testing some_x000D_
cardiovascular diseases and cardiovascular devices, they do not have the capability of testing the most_x000D_
important and common congenital cardiovascular pathology: coarctation of the aorta (COA). COA is a_x000D_
narrowing of the aorta with many morphologic variants. A physical COA simulator is much needed for_x000D_
designing, developing, evaluating and optimizing COA-related devices, especially the emerging vascular_x000D_
transcatheter stents, and for developing novel diagnostic methods for COA. COLLABORATION_x000D_
OPPORTUNITY: This collaboration allows ViVitro to investigate feasibility of adding the capability of testing_x000D_
of COA and COA-related devices to its product portfolio using an innovative approach. METHODOLOGY:_x000D_
This project uses clinical imaging data, image processing algorithms, and a unique computational fluid_x000D_
dynamics and lumped parameter modeling framework to provide details of the physiological pulsatile flow and_x000D_
pressures through the heart and the circulatory system. This information is required for developing and_x000D_
validating the setup to simulate the physiological condition. OPPORTUNITY: The new simulator can serve_x000D_
testing needs of medical-device companies that want to introduce new devices for COA. This simulator is also_x000D_
very attractive for academic research worldwide. This is particularly important because the industrial focus on_x000D_
vascular transcatheter stents and related devices is rapidly growing and the number of companies developing_x000D_
new vascular devices is greatly increasing. The new simulator can help ViVitro Labs to differentiate in the_x000D_
international market of endovascular device simulators and can create new jobs in Canada., program purpose french : COMPANY BACKGROUND: ViVitro Labs Inc. is a Canadian-based company that has provided_x000D_
cardiovascular and endovascular device test equipment and laboratory testing to a global market. It is the only_x000D_
Canadian company making cardiovascular and endovascular device test simulators. The ViVitro Pulse_x000D_
Duplicator system is the world's most cited and used in vitro hemodynamic testing system for commercial heart_x000D_
and valve devices. THE NEED: Although the ViVitro simulators have the capability of testing some_x000D_
cardiovascular diseases and cardiovascular devices, they do not have the capability of testing the most_x000D_
important and common congenital cardiovascular pathology: coarctation of the aorta (COA). COA is a_x000D_
narrowing of the aorta with many morphologic variants. A physical COA simulator is much needed for_x000D_
designing, developing, evaluating and optimizing COA-related devices, especially the emerging vascular_x000D_
transcatheter stents, and for developing novel diagnostic methods for COA. COLLABORATION_x000D_
OPPORTUNITY: This collaboration allows ViVitro to investigate feasibility of adding the capability of testing_x000D_
of COA and COA-related devices to its product portfolio using an innovative approach. METHODOLOGY:_x000D_
This project uses clinical imaging data, image processing algorithms, and a unique computational fluid_x000D_
dynamics and lumped parameter modeling framework to provide details of the physiological pulsatile flow and_x000D_
pressures through the heart and the circulatory system. This information is required for developing and_x000D_
validating the setup to simulate the physiological condition. OPPORTUNITY: The new simulator can serve_x000D_
testing needs of medical-device companies that want to introduce new devices for COA. This simulator is also_x000D_
very attractive for academic research worldwide. This is particularly important because the industrial focus on_x000D_
vascular transcatheter stents and related devices is rapidly growing and the number of companies developing_x000D_
new vascular devices is greatly increasing. The new simulator can help ViVitro Labs to differentiate in the_x000D_
international market of endovascular device simulators and can create new jobs in Canada., agreement title english : New cardiovascular simulator for coarctation of the aorta and coarctation-related devices, agreement title french : New cardiovascular simulator for coarctation of the aorta and coarctation-related devices, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-12-13, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada